Holen Sie sich die Stockscreener-App
239.89
0.82%
1.94
Handel nachbörslich:
239.89
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DHR?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$237.95
Offen:
$236.21
24-Stunden-Volumen:
2.86M
Relative Volume:
0.83
Marktkapitalisierung:
$169.45B
Einnahmen:
$24.27B
Nettoeinkommen (Verlust:
$3.50B
KGV:
49.37
EPS:
4.8589
Netto-Cashflow:
$5.02B
1W Leistung:
+2.08%
1M Leistung:
+4.97%
6M Leistung:
+24.39%
1J Leistung:
+0.81%
1-Tages-Spanne:
$235.07
$240.22
1-Wochen-Bereich:
$228.14
$241.26
52-Wochen-Spanne:
$171.00
$258.23
Danaher Corp Stock (DHR) Company Profile
Firmenname
Danaher Corp
Sektor
Branche
Telefon
(202) 828-0850
Adresse
2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC
Vergleichen Sie DHR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DHR
Danaher Corp
|
239.89 | 168.08B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
TMO
Thermo Fisher Scientific Inc
|
624.65 | 233.63B | 43.74B | 6.58B | 6.11B | 17.31 |
|
IDXX
Idexx Laboratories Inc
|
712.12 | 56.73B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
241.28 | 41.10B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
144.83 | 41.37B | 6.95B | 1.30B | 1.15B | 4.5696 |
Danaher Corp Stock (DHR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-10-08 | Herabstufung | Rothschild & Co Redburn | Buy → Neutral |
| 2025-07-11 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2025-04-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2025-03-14 | Hochstufung | Stifel | Hold → Buy |
| 2025-02-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-12-23 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-19 | Eingeleitet | Guggenheim | Buy |
| 2024-12-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-31 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-10-01 | Eingeleitet | Stephens | Overweight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Buy |
| 2024-04-17 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-01-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-12-18 | Eingeleitet | HSBC Securities | Hold |
| 2023-12-13 | Fortgesetzt | Wolfe Research | Peer Perform |
| 2023-12-07 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-19 | Eingeleitet | Raymond James | Outperform |
| 2023-05-01 | Eingeleitet | SVB Securities | Outperform |
| 2023-04-26 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-01-05 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-10-24 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-08-17 | Fortgesetzt | Bernstein | Outperform |
| 2022-07-20 | Eingeleitet | UBS | Buy |
| 2022-06-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-01-11 | Eingeleitet | Bernstein | Outperform |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-10 | Bestätigt | BofA Securities | Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-07-23 | Bestätigt | Goldman | Buy |
| 2021-07-16 | Eingeleitet | The Benchmark Company | Buy |
| 2021-04-07 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-03-03 | Fortgesetzt | Barclays | Overweight |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-25 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-06-16 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-04-02 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-03-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-02-03 | Bestätigt | Needham | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-11-15 | Fortgesetzt | Stifel | Hold |
| 2019-10-28 | Bestätigt | Needham | Buy |
| 2019-10-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2019-07-19 | Bestätigt | Needham | Buy |
| 2019-06-11 | Eingeleitet | Piper Jaffray | Neutral |
| 2019-05-30 | Eingeleitet | Wolfe Research | Outperform |
| 2019-04-17 | Bestätigt | Needham | Buy |
| 2019-02-28 | Bestätigt | Needham | Buy |
| 2019-02-25 | Hochstufung | Janney | Neutral → Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-04-20 | Bestätigt | Stifel | Buy |
Alle ansehen
Danaher Corp Aktie (DHR) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Is Investigating Danaher Corporation (DHR) And Encourages Investors to Connect - Stockhouse
How Investors Are Reacting To Danaher (DHR) Upbeat 2025 Outlook And Growing Synthetic Biology Ambitions - Yahoo Finance
JPM26: Danaher positioned to improve patient diagnostics - Medical Device Network
Danaher Corporation $DHR is Pacific Capital Partners Ltd's 6th Largest Position - MarketBeat
Robeco Schweiz AG Has $56.81 Million Stake in Danaher Corporation $DHR - MarketBeat
2026-01-13 | Bronstein, Gewirtz & Grossman, LLC Encourages Danaher Corporation (DHR) Stockholders to Inquire about Securities Investigation | NYSE:DHR | Press Release - Stockhouse
Nordea Investment Management AB Grows Stake in Danaher Corporation $DHR - MarketBeat
MGO One Seven LLC Has $4.31 Million Stock Position in Danaher Corporation $DHR - MarketBeat
Danaher Corp. Co-Founder Mitch Rales, Northpond Ventures Lead $43M Round for VieCure - citybiz
Mar Vista U.S. Quality Q4 2025 Top Contributors And Detractors - Seeking Alpha
Danaher’s Biopharma Boom: Why 2026 Could Be A Game-Changer! - Smartkarma
Danaher Forecasts 4Q Revenue at High-End of Guidance on Bioprocessing Strength -- Update - marketscreener.com
How To YieldBoost Danaher To 4.5% Using Options - Nasdaq
Danaher (NYSE:DHR) Releases FY 2025 Earnings Guidance - MarketBeat
(DHR) Danaher Expects 2025 Adjusted EPS at High-End of Range $7.70 to $7.80, vs. FactSet Est of $7.71 - marketscreener.com
Danaher Forecasts High-End of Prior Guidance, Citing Bioprocessing Strength - marketscreener.com
Form 8-K DANAHER CORP /DE/ For: Jan 12 - StreetInsider
Danaher CorpFor FY 2025, Anticipated Non-GAAP Adjusted EPS Expected To Be Toward High-End Of Guidance Range Of $7.70 To $7.80. - TradingView — Track All Markets
CEO of Danaher says 2025 ended strong as earnings near top target - Stock Titan
Sumitomo Mitsui Trust Group Inc. Purchases 94,080 Shares of Danaher Corporation $DHR - MarketBeat
Tema Etfs LLC Buys 11,035 Shares of Danaher Corporation $DHR - MarketBeat
Possible Bearish Signals With Danaher Insiders Disposing Stock - Yahoo Finance
Danaher Stock Finds Its Footing: Quiet Grind Higher While Wall Street Stays Overweight - AD HOC NEWS
Here's what to expect from Danaher's next earnings report - MSN
New York State Teachers Retirement System Reduces Position in Danaher Corporation $DHR - MarketBeat
Danaher Corporation $DHR Shares Sold by Associated Banc Corp - MarketBeat
Is Danaher Corp. the Quietest Power Stock on Wall Street – Or Just Overhyped? - AD HOC NEWS
Danaher Corp (NYSE:DHR) Passes the Caviar Cruise Screen for Quality Investors - Chartmill
Parnassus Investments LLC Trims Stock Position in Danaher Corporation $DHR - MarketBeat
Oregon Public Employees Retirement Fund Raises Stock Position in Danaher Corporation $DHR - MarketBeat
Danaher Corporation $DHR Shares Sold by SG Americas Securities LLC - MarketBeat
Promising Biotech Stocks To ConsiderJanuary 4th - MarketBeat
Rothschild Investment LLC Purchases 6,380 Shares of Danaher Corporation $DHR - MarketBeat
Nisa Investment Advisors LLC Has $39.48 Million Stock Position in Danaher Corporation $DHR - MarketBeat
Danaher Corporation $DHR Holdings Cut by Strategic Blueprint LLC - MarketBeat
Zacks Research Has Weak Outlook for Danaher FY2025 Earnings - MarketBeat
Danaher Corporation $DHR Shares Sold by Commonwealth Equity Services LLC - MarketBeat
Agilent Technologies: Why Execution Matters Most When the Cycle Turns - Investing.com
Is Danaher Corporation stock a buy in volatile marketsQuarterly Investment Review & AI Driven Stock Reports - ulpravda.ru
Is Danaher Corporation stock trading at a premium valuation2025 Retail Activity & Precise Swing Trade Alerts - ulpravda.ru
Danaher Corp. Stock: Silent Monster Move Or Overhyped Snoozefest? - AD HOC NEWS
Abhishek Bharti appointed Regional General Counsel of Danaher Corporation - Bar and Bench
Venturi Wealth Management LLC Has $14.39 Million Holdings in Danaher Corporation $DHR - MarketBeat
Buy Danaher Stock. It’s Ready to Put Post-Covid Malaise Behind It. - Barron's
$443.6 Bn Microtome Global Market Trends, Opportunities and Strategies, 2019-2024, 2025-2029F, 2034F: Top 10 Players Hold 26.56% Share Led by Danaher, Thermo Fisher Scientific, and Sakura Finetek - Yahoo Finance
Robeco Institutional Asset Management B.V. Increases Stock Holdings in Danaher Corporation $DHR - MarketBeat
Cerity Partners LLC Lowers Holdings in Danaher Corporation $DHR - MarketBeat
Danaher Corporation (NYSE:DHR) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Danaher stock slips as analysts lift targets ahead of JPM Healthcare Conference, earnings - TechStock²
$1000 Placed in Danaher a Decade Ago Would Be Valued at This Amount Now - Bitget
Where Danaher Stands With Analysts - Benzinga
Finanzdaten der Danaher Corp-Aktie (DHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):